According to World Health Organization statistics, about half of the world's population is at risk of malaria (WHO). As a result, numerous healthcare organisations have been more interested in solving this serious problem. The Melinda Gates Foundation and PATH, two global non-profit organisations, are trying to develop malaria prevention techniques and save the lives of many people in malaria-affected areas. Because Africa accounts for 90% of malaria occurrences, the launch of GlaxoSmithKline plc's first malaria vaccine is aimed primarily at this continent. Mosquirix was approved by the European Union in 2015 and is currently being tested in Africa as part of a pilot project.
Read More:
https://bloggerthrive.blogspot.com/2022/02/globally-impact-of-malaria-vaccines-and.html
Click here for Malaria Vaccines Market Report:
https://www.coherentmarketinsights.com/market-insight/malaria-vaccines-market-37
Click here for Malaria Vaccines Market Press Release:
